S Karrer1, R A G Aschoff2, R Dominicus3, G Krähn-Senftleben4, G G Gauglitz5, A Zarzour6, N Kerrouche7, R Chavda7, R-M Szeimies8. 1. Department of Dermatology, University Hospital Regensburg, Regensburg, Germany. 2. Department of Dermatology, University Hospital Carl Gustav Carus, Dresden, Germany. 3. Private Practice, Pro Derma Institute for Clinical Studies and Innovative Dermatology, Dülmen, Germany. 4. Private Practice, Neu-Ulm, Germany. 5. Private Practice, München, Germany. 6. Private Practice, Halle (Saale), Germany. 7. Galderma R&D, Sophia Antipolis, France. 8. Department of Dermatology and Allergology, Klinikum Vest GmbH, Recklinghausen, Germany.
Abstract
BACKGROUND: The efficacy and safety of methyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT) for actinic keratosis (AK) treatment has previously been demonstrated in several studies. OBJECTIVE: To evaluate patient-reported outcomes, effectiveness and tolerability of patient self-applied MAL DL-PDT. PATIENTS AND METHODS: An open study was conducted in Germany in patients with thin or non-hyperkeratotic and non-pigmented AK. At baseline, the investigator delimited the target anatomical area and skin preparation was discretionary. On day 1, the patient performed MAL DL-PDT at home, in accordance with instructions (after applying sunscreen and skin preparation by abrasive pad). Patient questionnaires were completed on day 1 and 3 months post-treatment. Effectiveness was assessed by investigator at 3 months. Pain and adverse events (AE) were recorded. RESULTS: Patients (n = 50) were mostly elderly (mean age: 73.4 years) men (86%). After treatment on day 1, 94% of patients were overall satisfied or very satisfied with the treatment and 98% found the instructions convenient. At 3 months, most patients were satisfied or very satisfied with treatment effectiveness (88%) and aspect of their skin (80%). At 3 months, 62% of overall lesions were completely clear. The main related AEs were mild and expected (erythema, procedural pain and skin burning sensation). CONCLUSIONS: Patient self-application of MAL DL-PDT resulted in high levels of patient satisfaction, effectiveness and tolerability.
BACKGROUND: The efficacy and safety of methyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT) for actinic keratosis (AK) treatment has previously been demonstrated in several studies. OBJECTIVE: To evaluate patient-reported outcomes, effectiveness and tolerability of patient self-applied MAL DL-PDT. PATIENTS AND METHODS: An open study was conducted in Germany in patients with thin or non-hyperkeratotic and non-pigmented AK. At baseline, the investigator delimited the target anatomical area and skin preparation was discretionary. On day 1, the patient performed MAL DL-PDT at home, in accordance with instructions (after applying sunscreen and skin preparation by abrasive pad). Patient questionnaires were completed on day 1 and 3 months post-treatment. Effectiveness was assessed by investigator at 3 months. Pain and adverse events (AE) were recorded. RESULTS:Patients (n = 50) were mostly elderly (mean age: 73.4 years) men (86%). After treatment on day 1, 94% of patients were overall satisfied or very satisfied with the treatment and 98% found the instructions convenient. At 3 months, most patients were satisfied or very satisfied with treatment effectiveness (88%) and aspect of their skin (80%). At 3 months, 62% of overall lesions were completely clear. The main related AEs were mild and expected (erythema, procedural pain and skin burning sensation). CONCLUSIONS:Patient self-application of MAL DL-PDT resulted in high levels of patient satisfaction, effectiveness and tolerability.
Authors: Sigrid Karrer; Rolf-Markus Szeimies; Wolfgang G Philipp-Dormston; Peter A Gerber; Welf Prager; Elisabeth Datz; Florian Zeman; Karolina Müller; Michael Koller Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875
Authors: L J McLellan; P O'Mahoney; S Logan; S Yule; C Goodman; A Lesar; L Fullerton; S Ibbotson; E Eadie Journal: Br J Dermatol Date: 2019-06-05 Impact factor: 9.302